Financial Data and Key Metrics Changes - The company reported $2.1 million in net product revenue for the first six weeks post-launch, with a cost of sales of $400,000 for 2025 compared to zero in 2024 [25][26] - Non-GAAP adjusted net loss was $41.4 million or $0.63 per share diluted for 2025, compared to a loss of $16.5 million or $0.61 per share diluted for 2024 [27] - The company ended 2025 with cash, cash equivalents, and investments of $164.3 million, bolstered by a $75 million private placement [27][28] Business Line Data and Key Metrics Changes - The FDA approved AvmapKefaxin Jakobak for KRAS mutated recurrent LGSOC, marking a significant milestone for the company [5][6] - The commercial launch of Abnapti Faxinga Copac has shown early traction with $2.1 million in revenue within six weeks [6][11] Market Data and Key Metrics Changes - The company has seen coverage from major insurers in the U.S., representing over 80% of lives, indicating strong market access [10][21] - The initial uptake of the product has been encouraging, with a mix of prescriptions from both academic and community settings [50][51] Company Strategy and Development Direction - The company aims to establish Abnapti Faxinga Copac as the new standard of care for KRAS mutated recurrent LGSOC, fundamentally changing the treatment paradigm [6][8] - Future milestones include advancing clinical programs and maintaining strong momentum in the commercial launch [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the product's potential impact on patients with high unmet needs and emphasized the importance of ongoing engagement with healthcare providers [10][22] - The company is optimistic about the second half of the year, expecting to build on early achievements and continue executing its strategic imperatives [16][29] Other Important Information - The company has entered into multiple agreements with specialty distributors and oncology group purchasing organizations to enhance market reach [16][21] - The NCCN committee plans to review the company's submission for broader treatment recommendations in October [20][75] Q&A Session Summary Question: Can you talk about the degree of off-label use currently seen? - Management noted that while they do not promote off-label uses, they have observed utilization in both labeled and wild-type populations, with reimbursement not being an issue to date [34][35] Question: What are the key indicators being tracked for launch performance? - Management indicated that they are monitoring engagement with healthcare providers, patient access, and overall market dynamics to gauge launch momentum [41][45] Question: What is the experience with payers regarding reimbursement? - Management reported that early experiences with payers have been positive, with minimal pushback and effective reimbursement processes in place [56][58] Question: How might the launch curve evolve with the integration of specialty distributors? - Management expects a steady uptick in patient adoption as the full distribution network is established, with ongoing engagement efforts to support this growth [66][77] Question: What is the current size of the sales force and future plans? - The company launched with a focused team of 16 sales representatives and currently has no plans to increase this number [99]